目的 探討百樂眠膠囊聯(lián)合氟西汀和利培酮治療抑郁癥的臨床療效。方法 收集2015年5月-2016年3月在西安市長安醫(yī)院接受治療的抑郁癥患者84例，根據(jù)治療方案的差別分為對照組（42例）和治療組（42例）。對照組口服鹽酸氟西汀分散片，20 mg/次，1次/d；同時口服利培酮片，2 mg/次，1次/d。治療組在對照基礎(chǔ)上口服百樂眠膠囊，4粒/次，2次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，同時比較兩組患者治療前后HAMD和WHOQOL-BREF評分變化情況。結(jié)果 治療后，對照組與治療組總有效率分別為80.95%和95.24%，兩組間差異具有統(tǒng)計學(xué)意義（P<0.05）。治療1、2、4周，兩組HAMD評分均較同組治療前顯著降低，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療2、4周，治療組的HAMD評分較對照組同期降低更顯著，且差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者生理健康、心理狀態(tài)、社會關(guān)系和周圍環(huán)境等WHOQOL-BREF評分較治療前升高（P<0.05）；且治療組WHOQOL-BREF評分比對照組的升高更明顯，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 百樂眠膠囊聯(lián)合氟西汀和利培酮治療抑郁癥療效顯著，可明顯緩解患者憂郁狀態(tài)，提高其生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Bailemian Capsules combined with fluoxetine and risperidone in treatment of depression. Methods Patients (84 cases) with depression in Changan Hospital of Xi'an from May 2015 to March 2016 were enrolled in this study and divided into control (42 cases) and treatment (42 cases) groups according to different treatments. The patients in the control group were po administered with Fluoxetine Hydrochloride Dispersible Tablets, 20 mg/time, once daily. At the same time, the patients were po administered with Risperidone Tablets, 2 mg/time, once daily. The patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. The patients in two groups were treated for 4 weeks. After treatment, clinical efficacy was evaluated, and the changes of HAMD and WHOQOL-BREF scores in two groups were compared before and after treatment. Results After treatment, the clinical effect in the control and treatment groups were 80.95% and 95.24%, respectively, and there was difference between two groups (P<0.05). After treatment for 1, 2, and 4 weeks, HAMD scores of two groups were obviously decreased, and the difference was statistically significant in the same group (P<0.05); After treatment for 2 and 4 weeks, HAMD scores of the treatment group decreased more obviously than those of the control group with significant difference (P<0.05). After treatment, the WHOQOL-BREF scores of physical health, psychological status, social relations, and surrounding environment in two groups were increased (P<0.05); And WHOQOL-BREF scores in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Bailemian Capsules combined with fluoxetine and risperidone has a significant clinical effect in treatment of depression, can relieve the depression state, and improve the quality of life, which has a certain clinical application value.